NCT05457582 - PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI | Biotech Hunter

Enrollment

1,212

Participants

Timeline

Start Date

March 30, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2030

Conditions

Acute Coronary SyndromeHyperlipidemiasPercutaneous Coronary InterventionCardiovascular Events

Interventions

DRUG

Placebo plus high-intensity statin

Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).

DRUG

PCSK 9 Inhibitor plus high-intensity statin

Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).

Trial Locations (1)

RECRUITING

Nanjing First Hospital, Nanjing